Prospective, descriptive study to assess latent tuberculosis infection (LTBI) among healthcare worker (HCW) in a tertiary hospital in a low-risk area.
identification and treatment of LTBI can substantially reduce the risk of development of disease and are important TB control strategies, especially in settings with a low tuberculosis (TB) incidence, where reactivation of LTBI often accounts for the majority of non-imported TB disease treatment of LTBI can substantially reduce the risk of development of disease. In Portugal the real prevalence of LTBI in low-risk HCWs has not been evaluated since they are not included in the periodic screening programs. It is important to diagnose TB infections in HCWs to prevent nosocomial transmission, particularly among immunocompromised patients. The risk for transmission varies by setting, occupational group, local prevalence of TB, patient population, and effectiveness of TB infection control measures. Prevention of active TB disease by treatment of LTBI is a critical component for public health. Tuberculin skin test (TST) is used worldwide to diagnose LTBI, whereas interferon-γ release assay (IGRA) are used in some countries according to their national TB programs. IGRA offers a potential method of serial testing to diagnose LTBI in HCWs, and it has better specificity than that of TST in one-time screening. Study participants should be identified and contacted by occupational health service. In association, study information should be disseminated through posters and institutional email.
Study Type
OBSERVATIONAL
Enrollment
100
All patients will receive: * Clinical evaluation; * Chest x-ray. * IGRA (or tuberculin skin test if immunocompromised) * Therapeutic proposal if eligible
Centro Hospitalar do Oeste - Torres Vedras
Torres Vedras, Lisbon District, Portugal
RECRUITINGNumber and percentage of latent tuberculosis diagnosis in healthcare workers
Patients with positive IGRA/tuberculin test screening and without clinical or radiological features of active Tuberculosis
Time frame: 1 year
Treatment acceptance for latent tuberculosis
Number of positive screening participants who accept and start treatment
Time frame: 1 year
Treatment completion
Number of patients who finished treatment
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.